FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

The phase III RV144 HIV-1 vaccine trial estimated vaccine efficacy (VE) to be 31.2%. This trial demonstrated that the presence of HIV-1-specific IgG-binding Abs to envelope (Env) V1V2 inversely correlated with infection risk, while the presence of Env-specific plasma IgA Abs directly correlated with risk of HIV-1 infection. Moreover, Ab-dependent cellular cytotoxicity responses inversely correlated with risk of infection in vaccine recipients with low IgA; therefore, we hypothesized that vaccine-induced Fc receptor-mediated (FcR-mediated) Ab function is indicative of vaccine protection. We sequenced exons and surrounding areas of FcR-encoding genes and found one FCGR2C tag SNP (rs114945036) that associated with VE against HIV-1 subtype CRF01_AE, with lysine at position 169 (169K) in the V2 loop (CRF01_AE 169K). Individuals carrying CC in this SNP had an estimated VE of 15%, while individuals carrying CT or TT exhibited a VE of 91%. Furthermore, the rs114945036 SNP was highly associated with 3 other FCGR2C SNPs (rs138747765, rs78603008, and rs373013207). Env-specific IgG and IgG3 Abs, IgG avidity, and neutralizing Abs inversely correlated with CRF01_AE 169K HIV-1 infection risk in the CT- or TT-carrying vaccine recipients only. These data suggest a potent role of Fc-γ receptors and Fc-mediated Ab function in conferring protection from transmission risk in the RV144 VE trial.

[1]  Jerome H. Kim,et al.  Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines , 2014, Science Translational Medicine.

[2]  Gary J. Nabel,et al.  Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination , 2014, Science Translational Medicine.

[3]  Allan C. deCamp,et al.  Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection , 2014, PloS one.

[4]  Holly Janes,et al.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. , 2013, The New England journal of medicine.

[5]  James Y. Dai,et al.  Immunoglobulin genes and the acquisition of HIV infection in a randomized trial of recombinant adenovirus HIV vaccine. , 2013, Virology.

[6]  Jerome H. Kim,et al.  Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG , 2013, Proceedings of the National Academy of Sciences.

[7]  Guido Ferrari,et al.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. , 2013, Immunity.

[8]  Allan C. deCamp,et al.  Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial , 2013, PloS one.

[9]  K. Shianna,et al.  Host genetics of HIV acquisition and viral control. , 2013, Annual review of medicine.

[10]  James Y. Dai,et al.  Two-stage testing procedures with independent filtering for genome-wide gene-environment interaction. , 2012, Biometrika.

[11]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[12]  G. Landucci,et al.  Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. , 2012, Blood.

[13]  Thomas A. Gerds,et al.  Fc Gamma Receptor IIIB (FcγRIIIB) Polymorphisms Are Associated with Clinical Malaria in Ghanaian Children , 2012, PloS one.

[14]  Tomer Hertz,et al.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env-V2 , 2012, Nature.

[15]  Jerome H. Kim,et al.  Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family , 2012, Journal of Virology.

[16]  S. Buchbinder,et al.  Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). , 2012, The Journal of infectious diseases.

[17]  Jerome H. Kim,et al.  Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. , 2012, The Lancet. Infectious diseases.

[18]  P. Gilbert,et al.  Nomenclature for immune correlates of protection after vaccination. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[20]  M. Biburger,et al.  FcγRIIB: a modulator of cell activation and humoral tolerance , 2012, Expert review of clinical immunology.

[21]  T. K. van den Berg,et al.  Phenotypic Variation in IgG Receptors by Nonclassical FCGR2C Alleles , 2012, The Journal of Immunology.

[22]  M. Carrington,et al.  Immunogenetics of spontaneous control of HIV. , 2012, Annual review of medicine.

[23]  C. Pauza,et al.  High Affinity Allele for the Gene of FCGR3A Is Risk Factor for HIV Infection and Progression , 2010, PloS one.

[24]  Kenneth G. C. Smith,et al.  Genetic variation, Fcγ receptors, KIRs and infection: the evolution of autoimmunity. , 2010, Current opinion in immunology.

[25]  V. Napolioni,et al.  Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy , 2010 .

[26]  M. Robb,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[27]  B. Haynes,et al.  Utilization of Immunoglobulin G Fc Receptors by Human Immunodeficiency Virus Type 1: a Specific Role for Antibodies against the Membrane-Proximal External Region of gp41 , 2009, Journal of Virology.

[28]  T. Kuijpers,et al.  Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B , 2009, Human mutation.

[29]  P. Bruhns,et al.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. , 2009, Blood.

[30]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[31]  S. Plotkin,et al.  Vaccines: correlates of vaccine-induced immunity. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  G. Landucci,et al.  FcγRIIa Genotype Predicts Progression of HIV Infection1 , 2007, The Journal of Immunology.

[33]  P. Gilbert,et al.  Recombinant gp120 Vaccine-Induced Antibodies Inhibit Clinical Strains of HIV-1 in the Presence of Fc Receptor-Bearing Effector Cells and Correlate Inversely with HIV Infection Rate1 , 2007, The Journal of Immunology.

[34]  A. Herr,et al.  IgA and IgA-specific receptors in human disease: structural and functional insights into pathogenesis and therapeutic potential , 2006, Springer Seminars in Immunopathology.

[35]  F. Nimmerjahn.  Activating and inhibitory FcγRs in autoimmune disorders , 2006, Springer Seminars in Immunopathology.

[36]  E. Vittinghoff,et al.  Case‐Only Analysis of Treatment–Covariate Interactions in Clinical Trials , 2006, Biometrics.

[37]  L. Zhao,et al.  Toward understanding MHC disease associations: partial resequencing of 46 distinct HLA haplotypes. , 2006, Genomics.

[38]  S. Gabriel,et al.  Efficiency and power in genetic association studies , 2005, Nature Genetics.

[39]  P. Lambert,et al.  Can successful vaccines teach us how to induce efficient protective immune responses? , 2005, Nature Medicine.

[40]  M. Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[41]  J. Ioannidis,et al.  The role of FcγRIIA and IIIA polymorphisms in autoimmune diseases , 2004 .

[42]  P. Morel,et al.  Allelic polymorphisms in the FcγRIIC gene can influence its function on normal human natural killer cells , 2002, Journal of Molecular Medicine.

[43]  W. Chambers,et al.  Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcgammaRIIC gene. , 1998, Blood.

[44]  J. V. D. van de Winkel,et al.  The human low affinity immunoglobulin G Fc receptor IIC gene is a result of an unequal crossover event. , 1993, The Journal of biological chemistry.

[45]  E. Rappaport,et al.  Differential expression of Fcγ RIIA, Fcγ RIIB and Fcγ RIIC in hematopoietic cells: Analysis of transcripts , 1993 .

[46]  S. S. Young,et al.  Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment , 1993 .

[47]  Peter B Gilbert,et al.  Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics. , 2014, Biostatistics.

[48]  J. Ravetch,et al.  FcγRs in health and disease. , 2011, Current topics in microbiology and immunology.

[49]  J. Ravetch,et al.  Fcgamma receptors as regulators of immune responses. , 2008, Nature reviews. Immunology.

[50]  J. Ravetch,et al.  Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.

[51]  G. Landucci,et al.  FcgammaRIIa genotype predicts progression of HIV infection. , 2007, Journal of immunology.

[52]  F. Nimmerjahn.  Activating and inhibitory FcgammaRs in autoimmune disorders. , 2006, Springer seminars in immunopathology.

[53]  J. Ioannidis,et al.  The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[54]  D. Musher,et al.  Association Between FcγRIIa-R131 Allotype and Bacteremic Pneumococcal Pneumonia , 2000 .

[55]  W. Chambers,et al.  Expression of Functional CD 32 Molecules on Human NK Cells Is Determined by an Allelic Polymorphism of the Fc g RIIC Gene , 1998 .

[56]  G. Siber.  Methods for estimating serological correlates of protection. , 1997, Developments in biological standardization.

[57]  Norman E. Breslow,et al.  Maximum Likelihood Estimation of Logistic Regression Parameters under Two‐phase, Outcome‐dependent Sampling , 1997 .

[58]  Siber Gr.  Methods for estimating serological correlates of protection. , 1997 .

[59]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .